|
Primary malignant neoplasm
|
0.020 |
GeneticVariation
|
group |
BEFREE |
CYC increases the risk of cancer, and HCQ decreases this risk in SLE patients, both in a dose-dependent manner.
|
28039419 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Patients were called in and a standard form was used for collecting demographic characteristics, indication for CYC, its cumulative dose and short term adverse events, defined as those causing discontinuation of CYC, hospitalization and/or death, long term adverse events, including infertility and malignancy, and outcome.
|
31840168 |
2019 |
|
Refractory anemias
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC and etanercept (ETN) were administered to 62 and 24 RA patients, respectively, who were confirmed with biopsy as having AA amyloidosis.
|
22879465 |
2012 |
|
Angina, Unstable
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eighty-four consecutive type 2 diabetic patients with unstable angina (UA) were included from January 2018 to June 2018 to calculate calcification scores using computerized tomographic angiography (CTA), and the patients were divided into 2 groups: high calcification score group (HCS group) and low calcification score group (LCS group).
|
31452690 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC and etanercept (ETN) were administered to 62 and 24 RA patients, respectively, who were confirmed with biopsy as having AA amyloidosis.
|
22879465 |
2012 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC remains an important treatment option for Behçet's syndrome (BS) patients with life-threatening manifestations.
|
31840168 |
2019 |
|
Blood Platelet Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
This study of a family with the platelet disorder characterized by a defect of the platelet P2(CYC) receptor supports our hypothesis that the full complement of the platelet ADP receptors is essential for normal platelet secretion and that some patients with the common, ill-defined diagnosis of PSD are actually heterozygous for the defect.
|
11073862 |
2000 |
|
Bloom Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated short and long term adverse events associated with CYC use in BS patients.
|
31840168 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Chondrocytic HCS-2/8 cells and breast cancer MDA231 cells produce over 6 times more CCN2 than any other cell type.
|
17291666 |
2007 |
|
Chediak-Higashi Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We used two human CHS cell lines SW1353 and HCS-2/8 to analyze the expression profiles of ADAM8 in CHS cells compared with the normal chondrocytes.
|
31305294 |
2019 |
|
Cystinuria
|
0.010 |
Biomarker
|
disease |
BEFREE |
The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria.
|
23794250 |
2013 |
|
Encephalitis, St. Louis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two subcohorts of treated SLE patients were defined on the basis of treatment with antimalarials (n = 1942) and other immunosuppressants (AZA, CYC, ciclosporin, MTX, MMF or rituximab; n = 2175).
|
28039412 |
2017 |
|
Failure to Thrive
|
0.010 |
Biomarker
|
disease |
BEFREE |
The affected siblings display a recognizable phenotype which is similar to atypical HCS with regard to growth failure and neuro-muscular features, but is characterized by lack of cystinuria.
|
23794250 |
2013 |
|
Head and Neck Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this chapter, we describe the HCS assay methods to measure IL-6-induced STAT3 signaling pathway activation in head and neck tumor cell lines as revealed by the expression and subcellular distribution of pSTAT3-Y705, pSTAT3-S727, and U-STAT3.
|
29082496 |
2018 |
|
Leukopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Leucopenia occurred more often in the CYC group compared to the TwHF group (P = 0.034).
|
31713733 |
2020 |
|
Lupus Nephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with a combined immunosuppressive agent is superior to routine CYC only therapy in lupus nephritis.
|
30488367 |
2019 |
|
Retinitis Pigmentosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CYCS: cytochrome c; bRHO<sup>P23H</sup>: bovine RHO<sup>P23H</sup>; Cas9: CRISPR associated protein 9; dpf: days post-fertilization; eGFP: enhanced green fluorescent protein; GNAT1: guanine nucleotide-binding protein G(t) subunit alpha-1 aka rod alpha-transducin; HSPA1A/hsp70: heat shock protein of 70 kilodaltons; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1A/1B light chain 3; mRFP: monomeric red fluorescent protein; RHO: rhodopsin; RP: retinitis pigmentosa; RPE65: retinal pigment epithelium-specific 65 kDa protein: sfGFP: superfolding GFP; sgRNA: single guide RNA; WGA: wheat germ agglutinin; <i>RHO<sub>p</sub></i>: the <i>Xenopus laevis RHO.2.L</i> promoter.
|
30975014 |
2019 |
|
Skin Manifestations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The aim of the study was to compare the efficacy and safety of RTX compared with CYC in retarding the progression of interstitial lung disease and skin manifestations of primary SSc.
|
30053212 |
2018 |
|
Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, adverse events may occur with CYC and this has led to increased use of biologic agents in other vasculitides.
|
31840168 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this review, we will highlight the macrophage functions in the skeleton, in the maintenance of the HCS niches, and their importance in bone metastasis.
|
28247013 |
2017 |
|
Reactive systemic amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC and etanercept (ETN) were administered to 62 and 24 RA patients, respectively, who were confirmed with biopsy as having AA amyloidosis.
|
22879465 |
2012 |
|
Floppy infant syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypotonia-cystinuria syndrome (HCS, OMIM606407) is characterized by infantile hypotonia, poor feeding, and growth hormone deficiency.
|
23794250 |
2013 |
|
Somatotropin deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypotonia-cystinuria syndrome (HCS, OMIM606407) is characterized by infantile hypotonia, poor feeding, and growth hormone deficiency.
|
23794250 |
2013 |
|
Frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> 4HPR: 4-hydroxy(phenyl)retinamide; AKT: AKT1 serine/threonine kinase 1; ALS: amyotrophic lateral sclerosis; ATG: autophagy related; AVs: autophagic vesicle; C9orf72: chromosome 9 open reading frame 72; CASP3: caspase 3; CHAT: choline O-acetyltransferase; CYCS: cytochrome c, somatic; DIV: day in vitro; FTD: frontotemporal dementia; FUS: FUS RNA binding protein; GFP: green fluorescent protein; hiPSCs: human induced pluripotent stem cells; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MNs: motoneurons; mRFP: monomeric red fluorescent protein; MTOR: mechanistic target of rapamycin kinase; NFE2L2/NRF2: nuclear factor, erythroid 2 like 2; RARA: retinoic acid receptor alpha; SLC18A3/VACHT: solute carrier family 18 (vesicular acetylcholine transporter), member 3; SQSTM1/p62: sequestosome 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy.
|
30939964 |
2019 |
|
Arterial aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms.
|
30107448 |
2018 |